Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression-free survival (PFS) and to evaluate the indications f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Shimose, Shigeo, Kawaguchi, Takumi, Tanaka, Masatoshi, Iwamoto, Hideki, Miyazaki, Ken, Moriyama, Etsuko, Suzuki, Hiroyuki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Suga, Hideya, Yamaguchi, Taizo, Yokokura, Yoshinori, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2020
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7400966/
https://ncbi.nlm.nih.gov/pubmed/32782543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11758
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados